Paper14729660
mRNA is an endogenous ligand for Toll-like receptor 3.
Karikó K and 4 others. J Biol Chem, 2004. Cited by 863 papers, by iCite.
Cite this record
ConductScience Library. mRNA is an endogenous ligand for Toll-like receptor 3. Papers, record 14729660. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/14729660
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics31
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Membrane Glycoproteins | Major topic |
| Receptors, Cell Surface | Major topic |
| Blotting, Northern | |
| Cell Line | |
| Dendritic Cells | |
| Dose-Response Relationship, Drug | |
| Enzyme Inhibitors | |
| Enzyme-Linked Immunosorbent Assay | |
| Genistein | |
| Humans | |
| Interleukin-1 Receptor-Associated Kinases | |
| Interleukin-8 | |
| Ligands | |
| Luciferases | |
| NF-kappa B | |
| Necrosis | |
| Nucleic Acid Conformation | |
| Plasmids | |
| Protein Kinases | |
| RNA | |
| RNA, Double-Stranded | |
| RNA, Messenger | |
| Signal Transduction | |
| Staurosporine | |
| Toll-Like Receptor 3 | |
| Toll-Like Receptors | |
| Transcription, Genetic | |
| Transfection | |
| Tumor Necrosis Factor-alpha | |
| Tyrosine | |
| Up-Regulation |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| AI 50484 | NIAID NIH HHS | United States | R01AI050484 | PubMed and NIH | NIH RePORTER |
| HL 62060-04 | NHLBI NIH HHS | United States | PubMed | PubMed | |
| R01HL062060 | NIH | NIH RePORTER |
Cited by457
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 863 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42853631 | mRNA-based therapies: From molecular discovery to clinical revolution. | Genet Mol Biol | 2026 | https://conductscience.org/library/papers/42853631 | PubMed |
| 42764981 | Lipid nanoparticles as active biointerfaces: From membrane interaction to systemic dysregulation. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42764981 | PubMed |
| 42460750 | Cancer Vaccine Development: Toward Artificial Intelligence-Assisted Personalized Cell Membrane Nanovaccine. | Small | 2026 | https://conductscience.org/library/papers/42460750 | PubMed |
| 42344670 | Engineering bone tissue with mRNA: from molecular design and delivery to clinical applications. | Mater Today (Kidlington) | 2025 | https://conductscience.org/library/papers/42344670 | PubMed |
| 42321218 | Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/42321218 | PubMed |
| 42294684 | IFN-I exacerbates the inflammatory response of epithelial cells to Chlamydia trachomatis infection by enhancing TLR3 expression. | mBio | 2026 | https://conductscience.org/library/papers/42294684 | PubMed |
| 42125067 | mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42125067 | PubMed |
| 42076082 | RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42076082 | PubMed |
| 41943009 | A comprehensive analysis of the use of nucleoside analogues in RNA therapeutics. | J Transl Med | 2026 | https://conductscience.org/library/papers/41943009 | PubMed |
| 41769202 | Nucleic acid-based therapeutics to restore joint homeostasis in age-related and post-traumatic arthritis. | NPJ Biomed Innov | 2026 | https://conductscience.org/library/papers/41769202 | PubMed |
| 41750365 | mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection. | Biomolecules | 2026 | https://conductscience.org/library/papers/41750365 | PubMed |
| 41732665 | Effect of type I collagen on TLR-3 induced MMP-13 expression in human periodontal ligament fibroblasts. | J Oral Biol Craniofac Res | 2026 | https://conductscience.org/library/papers/41732665 | PubMed |
| 41600889 | Making Sense from Structure: What the Immune System Sees in Viral RNA. | Viruses | 2026 | https://conductscience.org/library/papers/41600889 | PubMed |
| 41479562 | mRNA-Based Personalized Cancer Vaccines: Opportunities, Challenges and Outcomes. | Acta Naturae | 2025 | https://conductscience.org/library/papers/41479562 | PubMed |
| 41155941 | RNA Therapeutics: Delivery Problems and Solutions-A Review. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41155941 | PubMed |
| 41098300 | Impact of Allostatic Load on Chronic Hepatitis B and C: A Narrative Review. | Cureus | 2025 | https://conductscience.org/library/papers/41098300 | PubMed |
| 41053377 | Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies. | NPJ Metab Health Dis | 2025 | https://conductscience.org/library/papers/41053377 | PubMed |
| 40969676 | Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40969676 | PubMed |
| 40905915 | Using modified mRNA for cardiomyocyte proliferation and cardiac genetic disease modelling and treatment. | Biochem Soc Trans | 2025 | https://conductscience.org/library/papers/40905915 | PubMed |
| 40881859 | Unraveling the potential: mRNA therapeutics in oncology. | Front Oncol | 2025 | https://conductscience.org/library/papers/40881859 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CXCL8 | 3576 | PubTator's text mining | https://conductscience.org/library/genes/3576 | NCBI Gene |
| IRF1 | 3659 | PubTator's text mining | https://conductscience.org/library/genes/3659 | NCBI Gene |
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| TLR3 | 7098 | PubTator's text mining | https://conductscience.org/library/genes/7098 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/14729660
GET https://conductscience.org/api/papers/v1/14729660/cited_by?page=2